|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009491,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0033860,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C1122087,
umls-concept:C1274040,
umls-concept:C1579762,
umls-concept:C1696465,
umls-concept:C2587213
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-15
|
|
pubmed:abstractText |
Biologic therapies such as adalimumab, a tumour necrosis factor antagonist, are safe and effective in the treatment of moderate to severe chronic plaque psoriasis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
158
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
558-66
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18047523-Adult,
pubmed-meshheading:18047523-Anti-Inflammatory Agents,
pubmed-meshheading:18047523-Antibodies, Monoclonal,
pubmed-meshheading:18047523-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18047523-Antirheumatic Agents,
pubmed-meshheading:18047523-Dose-Response Relationship, Drug,
pubmed-meshheading:18047523-Double-Blind Method,
pubmed-meshheading:18047523-Female,
pubmed-meshheading:18047523-Humans,
pubmed-meshheading:18047523-Male,
pubmed-meshheading:18047523-Methotrexate,
pubmed-meshheading:18047523-Psoriasis,
pubmed-meshheading:18047523-Quality of Life,
pubmed-meshheading:18047523-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
|
|
pubmed:affiliation |
Service de Dermatologie, Hôpital Cantonal Universitaire, 24 Rue Micheli-du-Crest, Geneva 1211, Switzerland. Jean.Saurat@medecine.unige.ch
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
